Controversies in hypertension treatment

Current Vascular Pharmacology

Volumn 8, Issue 6, 2010, Pages 731-732

  Banach, Maciej ^a   Kjeldsen, Sverre E ^b   Narkiewicz, Krzysztof ^c  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LIPID; NEBIVOLOL; PROPRANOLOL;

ANGINA PECTORIS; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DISEASE ASSOCIATION; DRESSLER SYNDROME; DRUG COST; DRUG EFFICACY; EDITORIAL; GERIATRIC PATIENT; HEALTH CARE COST; HEALTH CARE SYSTEM; HEART ATRIUM FIBRILLATION; HEMOSTASIS; HIGH RISK PATIENT; HYPERKALEMIA; HYPERTENSION; INSULIN SENSITIVITY; KIDNEY DYSFUNCTION; MORBIDITY; MORTALITY; PATIENT COMPLIANCE; PATIENT EDUCATION; PRACTICE GUIDELINE; PRIMARY PREVENTION; PROTEINURIA; PUBLICATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK BENEFIT ANALYSIS; RISK REDUCTION; SCIENTIFIC LITERATURE; STROKE;

EID: 77958083667     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016110793563915     Document Type: Editorial

References (21)

1. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121-2158.
2. Mancia G, Grassi G. What changes we may expect in 2010 hypertension diagnosis and management: insights from the European update document Curr Vasc Pharmacol 2010; 8: 788-791.
3. Bielecka-Dabrowa A, Aronow WS, Rysz J, Banach M. Current place of beta-blockers in the treatment of hypertension. Curr Vasc Pharmacol 2010; 8: 733-741.
4. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: 1665-1683.
5. Turnbull F, Neal B, Ninomiya T, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008; 336: 1121-1123.
6. De Caterina AR, Leone AM. Why beta-blockers should not be used as first choice in uncomplicated hypertension. Am J Cardiol 2010; 105: 1433-1438.
7. Desai RV, Banach M, Ahmed MI, et al. Impact of baseline systolic blood pressure on long-term outcomes in patients with advanced chronic systolic heart failure (insights from the BEST trial). Am J Cardiol 2010; 106: 221-227.
8. Verdecchia P, Angeli F, Mazzotta G, Ambrosio G, Reboldi G. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in the treatment of hypertension: should they be used together? Curr Vasc Pharmacol 2010; 8: 742-746.
9. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547-553.
10. Aronow WS. Why and how we should treat elderly patients with hypertension? Curr Vasc Pharmacol 2010; 8: 780-787.
11. Sethi A, Arora RR. Ambulatory blood pressure as a predictor of cardiovascular risk. Arch Med Sci 2009; 5: 3-9.
12. Chrostowska M, Narkiewicz K. Improving patient compliance with hypertension treatment: mission possible? Curr Vasc Pharmacol 2010; 8: 804-807.
13. Stepien M, Banach M, Jankowski P, Rysz J. Clinical implications of non-invasive measurement of central aortic blood pressure. Curr Vasc Pharmacol 2010; 8: 747-52.
14. Rossi GP, Seccia TM, Pessina AC. Secondary hypertension: the ways of management. Curr Vasc Pharmacol 2010; 8: 753-768.
15. Shantsila A, Shantsila E, Lip GYH. Malignant hypertension: a rare problem or is it underdiagnosed? Curr Vasc Pharmacol 2010; 8: 775-779.
16. Karagiannis A, Tziomalos K, Anagnostis P, et al. The effect of antihypertensive agents on insulin sensitivity, lipids and haemostasis. Curr Vasc Phar-macol 2010; 8: 792-803.
17. Aksnes TA, Kjeldsen SE. A link between hypertension and atrial fibrillation: methods of treatment and prevention. Curr Vasc Pharmacol 2010; 8: 769-774.
18. Banach M, Barylski M, Rysz J. What should be the optimal levels of blood pressure? J-curve phenomenon. The scene after ACCORD BP publication. Evide-Based Cardiol 2010; 1: 113-120.
19. The ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1575-1585.
20. Verdecchia P, Angeli F, Cavallini C, et al. The optimal blood pressure target for patients with coronary artery disease. Curr Cardiol Rep 2010; 12: 302-306.
21. Cooper-DeHoff RM, Handberg EM, Mancia G, et al. INVEST revisited: review of findings from the International Verapamil SR-Trandolapril Study. Expert Rev Cardiovasc Ther 2009; 7: 1329-1340.